Package Leaflet: Information for the User
Sapropterin Tarbis 100 mg Soluble Tablets EFG
sapropterin dihydrochloride
Read this leaflet carefully before you start taking this medicine because it contains important information for you.
Sapropterin contains the active ingredient sapropterin, which is a synthetic copy of a substance found in the body called tetrahydrobiopterin (BH4). BH4 is necessary in the body to convert an amino acid called phenylalanine into another amino acid called tyrosine.
Sapropterin is used to treat hyperphenylalaninemia (HPA) or phenylketonuria (PKU) in patients of any age. HPA and PKU are caused by abnormally high levels of phenylalanine in the blood that can be harmful. Sapropterin reduces these levels in some patients who respond to BH4 and may help increase the amount of phenylalanine that can be included in the diet.
This medication is also used to treat a hereditary disease called tetrahydrobiopterin deficiency in patients of any age, in which the body cannot produce enough BH4. Because BH4 levels are very low, the body cannot use phenylalanine properly, and levels of this amino acid increase, having harmful effects. By substituting the BH4 that the body cannot produce, sapropterin reduces the damaging excess of phenylalanine in the blood and increases tolerance to phenylalanine in the diet.
Do not take Sapropterina Tarbis
If you are allergic to sapropterin or any of the other components of this medication (listed in section 6).
Warnings and precautions
Consult your doctor or pharmacist before starting sapropterin, especially:
When receiving treatment with sapropterin, your doctor will perform blood tests to verify the content of phenylalanine and tyrosine and decide to adjust the dose of sapropterin or the diet as necessary.
You must continue the dietary treatment according to your doctor's recommendations. Do not change your diet without informing your doctor. Even when taking sapropterin, if your blood phenylalanine levels are not well controlled, you may experience severe neurological problems. Your doctor must continue to monitor your blood phenylalanine levels frequently during sapropterin treatment,to ensure they are not too high or too low.
Use of Sapropterina Tarbis with other medications
Inform your doctor or pharmacist if you are taking, have taken recently, or may need to take any other medication. In particular, you must inform your doctor if you are using:
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, or think you may be pregnant, consult your doctor or pharmacist before using this medication.
If you are pregnant, your doctor will instruct you on how to control your phenylalanine levels properly. If they are not strictly controlled before pregnancy or when you become pregnant, it may be harmful to you and your baby. Your doctor will supervise the restriction of phenylalanine intake with diet before and during pregnancy.
If a strict diet does not reduce phenylalanine levels sufficiently in the blood, your doctor will consider whether you should take this medication.
You should not use this medication during breastfeeding.
Driving and operating machinery
Sapropterin is not expected to affect your ability to drive and operate machinery.
Important information about some components of Sapropterina Tarbis
This medication contains less than 1 mmol of sodium (23 mg) per tablet; it is essentially "sodium-free".
Follow the exact administration instructions for this medication as indicated by your doctor. If in doubt, consult your doctor again.
Dose for PKU
The recommended initial dose of sapropterin in patients with PKU is 10 mg per kg of body weight. Take sapropterin once a day, with a meal to increase absorption, and at the same time every day, preferably in the morning. Your doctor may adjust the dose, generally between 5 and 20 mg daily per kg of body weight, according to your condition.
Dose for BH4 deficiency
The recommended initial dose of sapropterin in patients with BH4 deficiency is 2 to 5 mg per kg of body weight. Take sapropterin with a meal to increase absorption. Divide the total daily dose into 2 or 3 doses administered throughout the day. Your doctor may adjust the dose up to 20 mg daily per kg of body weight, according to your condition.
The following table is an example of how to calculate the appropriate dose
Body weight (kg) | Number of 100 mg tablets (dose of 10 mg/kg) | Number of 100 mg tablets (dose of 20 mg/kg) |
10 | 1 | 2 |
20 | 2 | 4 |
30 | 3 | 6 |
40 | 4 | 8 |
50 | 5 | 10 |
Administration form
For patients with PKU, the total daily dose is taken once a day and at the same time every day, preferably in the morning.
For patients with BH4 deficiency, the total daily dose is divided into 2 or 3 doses distributed throughout the day.
Use in all patients
Deposit the prescribed tablets in a glass or cup of water, exactly as described below, and stir until dissolved.
The tablets may take a few minutes to dissolve. To dissolve the tablets faster, you can crush them. You may observe small particles in the solution that will not affect the efficacy of the medication. Drink the prepared sapropterin solution with a meal within 15 or 20 minutes of preparation.
Do not ingest the desiccant capsule included in the bottle.
Use in patients with a body weight over 20 kg
Deposit the tablets in a glass or cup (120 to 240 ml) of water and stir until dissolved.
Use in children up to 20 kg of body weight
The dose is based on body weight, which will change as the child grows. Your doctor will instruct you:
The child should drink the sapropterin solution with a meal.
Administer the child the prescribed amount of solution within 15 or 20 minutes of preparation. If you cannot administer the dose to the child within 15 or 20 minutes of preparation, you will need to prepare a new solution, as unused solution should not be used after 20 minutes.
Materials needed to prepare and administer the child's sapropterin dose
Ask your doctor for the medication cup to dissolve the tablets and the oral syringe of 10 ml or 20 ml if you do not have these materials.
Steps for preparation and taking the dose:
If you take more Sapropterin Tarbis than you should
If you take more sapropterin than prescribed, you may experience adverse effects that may include headaches and dizziness. If you take more sapropterin than prescribed, inform your doctor or pharmacist immediately.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicological Information Service, phone: 91 562 04 20, indicating the medication and the amount ingested.
If you forget to take Sapropterin Tarbis
Do not take a double dose to compensate for the missed doses. Take the next dose at the usual time.
If you interrupt treatment with Sapropterin Tarbis
Do not interrupt treatment with sapropterin without first consulting your doctor, as this may increase blood phenylalanine levels.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medications, this medication may produce adverse effects, although not everyone will experience them.
Few cases of allergic reactions (such as skin rashes and severe reactions) have been reported. Their frequency is unknown (the frequency cannot be estimated from the available data).
If you have inflamed, red, and intensely itchy areas (urticaria), nasal discharge, rapid or irregular pulse, tongue or throat inflammation, sneezing, hissing while breathing, severe respiratory difficulty, or dizziness, you may be experiencing a severe allergic reaction to the medication. If you experience these symptoms, consult your doctor immediately.
Very Common Adverse Effects(may affect more than 1 in 10 people)
Headache and nasal discharge.
Common Adverse Effects(may affect up to 1 in 10 people)
Sore throat, congestion or nasal blockage, cough, diarrhea, vomiting, stomach pain, low phenylalanine levels in blood tests, indigestion, and general discomfort (nausea) (see section 2: "Warnings and Precautions").
Unknown Adverse Effects(cannot be estimated from available data)
Gastritis (inflammation of the stomach lining), esophagitis (inflammation of the esophagus lining).
Reporting Adverse Effects
If you experience any type of adverse effect, consult your doctor, pharmacist, or nurse, even if it is a possible adverse effect not listed in this prospectus. You can also report them directly through the Spanish System for Pharmacovigilance of Medicinal Products for Human Use:https://www.notificaram.es.
By reporting adverse effects, you can contribute to providing more information about the safety of this medication.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the bottle and on the packaging after CAD. The expiration date is the last day of the month indicated.
This medication does not require any special storage temperature.
Keep the bottle perfectly closed to protect it from moisture.
Medications should not be thrown down the drains or in the trash. Dispose of the containers and medications you no longer need at the SIGRE collection point at the pharmacy. Ask your pharmacist how to dispose of the containers and medications you no longer need. By doing so, you will help protect the environment.
Composition of Sapropterina Tarbis
The active ingredient is sapropterin dihydrochloride.
Each tablet contains 100 mg of sapropterin dihydrochloride (equivalent to 77 mg of sapropterin).
The other components are
Manitol (E421), ascorbic acid (E300), crospovidone (Type A), riboflavin (E101), anhydrous colloidal silica, stearate and sodium fumarate.
Appearance of the product and contents of the packaging
Round speckled tablet, white to light yellow in color, with an approximate diameter of 9.5 mm, engraved with “I 1” on one side and smooth on the other.
Sapropterina Tarbis is available in child-resistant bottles of 30 and 120 soluble tablets. Each bottle contains a small plastic desiccant tube (silica gel and oxygen scavenger).
Only some packaging sizes may be marketed.
Marketing Authorization Holder
Tarbis Farma S.L.
Gran Vía Carlos III, 94
08028 Barcelona
Spain
Responsible for manufacturing
Amarox Pharma B.V.
Rouboslaan 32
Voorschoten, 2252TR
Netherlands
This medicine is authorized in the member states of the European Economic Area with the following names:
Germany:Sapropterin Amarox 100 mg Tabletten zur Herstellung einer Lösung zum Einnehmen
Netherlands:Sapropterine Amarox 100 mg oplosbare tabletten
Spain:Sapropterina Tarbis 100 mg comprimidos solubles EFG
Last review date of this leaflet: June 2024
Detailed information about this medicine is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es/
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.